System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Caroline Robert is an expert in Oncology at Institut Gustave Roussy (France). As of October 2026, ScienceLeadR ranks Caroline Robert in the top 1% of experts worldwide for Skin Neoplasms, Melanoma and Carcinoma. Caroline Robert has authored 972 publications, the most recent in 2026, and is an investigator in 80 clinical trials, 12 of them ongoing. SLR score: 4,536 (community average: 125). How the SLR is computed.

LeadR Profile

Caroline Robert Institut Gustave Roussy France
4 536 ScienceLeadR Reputation 4536

Unlock

Register Login
Network Map

Oncology

Subspecialties: Neurology - Dermatology - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1999 - 2026
Source: PubMed

GHU AP-HP. Université Paris-Saclay

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 972

Citations

Citations: 144 619 1st author: 88 Last author: 168 Unique author: 17

Main journals

J Clin Oncol 159
Eur J Cancer 96
Ann Oncol 69
Cancer Res 43
Lancet Oncol 36

Best Journals

J Clin Oncol 81
Ann Oncol 37
Lancet Oncol 36

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).
PMID 42823486 — cells, molecular biology, melanoma, neoplasm metastasis, neoadjuvant therapy, therapeutics		Nat Med Top journal20260
Biodistribution, shedding, and transmissibility of vusolimogene oderparepvec (RP1).
PMID 42582160 — injections, herpes simplex, blood, neoplasms, simplexvirus, viruses, therapeutics, infections		Front Oncol20260
COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.
PMID 42585631 — safety, melanoma		J Clin Oncol Top journal20260
Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.
PMID 42579833 — safety, melanoma, therapeutics		J Clin Oncol Top journal20261
Real-world treatment patterns in stage III and IV melanoma patients: insights from a global multi-center chart review study.
PMID 42564088 — melanoma, multiple chronic conditions, immune system diseases, therapeutics		Front Immunol20260

Clinical Studies 80

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 9 Study Chair: 2

By phase:

Phase 3 35
Phase 2 28
N/A 6
Phase 1 6
Phase 1/Phase 2 4
Phase 2/Phase 3 1

By status:

Completed 39
Active not recruiting 14
Recruiting 10
Terminated 8
Unknown 8
Withdrawn 1

By type:

Interventional 76
Observational 4

By Monocentric/Multicentric:

monocentric 11
multicentric2to4 1
multicentric5to9 6
multicentricup10 62

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

12 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A clinical study of V940 and pembrolizumab in people with melanoma (V940 012)
2024-519605-36-00 — melanoma, rna, messenger		Phase 2Recruiting2025
Phase 3 Study of V940 and Pembrolizumab in Resected Melanoma
2023-503652-27-00 — melanoma, rna, messenger		Phase 3Active not recruiting2023
NEOREM NEO 1 NEOREM Neo adjuvant Immunotherapy Master Trial for Localized Cancers NEO 1 Neo adjuvant immunotherapy in patients with localized melanoma
2025-522127-95-00 — quality of life, disease-free survival, melanoma, neoplasms, immunotherapy, therapeutics		Phase 2Recruiting2026
A Study of Subcutaneous Nivolumab Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY 127)
2022-500967-11-00 — pharmaceutical preparations, melanoma, nivolumab		Phase 3Recruiting2023
Neo adjuvant Immunotherapy in Patients With Localized Melanoma
NCT07230613 — injections, melanoma, neoplasms, solutions, immunotherapy, neoadjuvant therapy, nivolumab, therapeutics, ipilimumab		Phase 2Recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS